Stockhub

Poxel S.A.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

3 September 2022

  • curprev 23:0123:01, 3 September 2022 >Nick 1,377 bytes +1,377 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin re..."
Retrieved from "https://stockhub.co/research/Poxel_S.A."